Genmab's chief development officer sells shares in US
On Tuesday, a transaction involving Genmab shares worth USD 390,771 took place in the US.
by marketwire, translated by daniel pedersen
Executive Vice President & Chief Development Officer at Genmab Judith Klimovsky sold 900 American Depository Shares, ADSs, at a price per share of USD 434.2 on Tuesday, the company writes in a press release.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.